Overview
Vesugen is a synthetic tetrapeptide (Lys-Glu-Asp-Gly) developed within Vladimir Khavinson's peptide bioregulator research programme at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a "vascular/endothelial bioregulator" — part of the same family of very short peptides discussed elsewhere on this site (including Epithalon, Pinealon and others), designed on the theory that each organ or tissue system produces its own short peptide signals that decline with age, and that a synthetic analogue of that signal can be studied for tissue-specific research effects. Vesugen is specifically studied in relation to vascular endothelium — the cell layer lining blood vessels — and its role in microcirculation and vascular integrity during ageing.
It is important to state plainly what the evidence base for Vesugen actually looks like: almost all published research originates from Khavinson's own laboratories or closely affiliated Russian institutions, published largely in Russian-language journals or their English-language sister publications (e.g.
Bulletin of Experimental Biology and Medicine,
Advances in Gerontology). There is no independent Western replication, no registered Western clinical trial, and no regulatory approval for Vesugen as a medicine in the EU, UK, or Ireland. Readers should treat the findings below as a specific, narrow research literature — not as consensus science — and weigh that context heavily.
Within that literature, Vesugen is studied mainly in aged rodent and cell-culture models for effects on endothelial cell function, microcirculatory markers, and vascular ageing indices, alongside some small-scale Russian human research examining vascular and circulatory parameters in older adults. This guide is for educational and research purposes only. Not medical advice.
Clinical & Research Status
| Evidence Type |
Status |
| Human RCT (Western) |
✗ |
| Human Studies (Russian, small-scale) |
✔ (limited) |
| Animal Studies |
✔ |
| In Vitro (endothelial cell culture) |
✔ |
| Regulatory Approval (Ireland/EU) |
✗ |
Mechanism of Action
Vesugen's proposed mechanism follows the same theoretical framework used across Khavinson's short peptide bioregulator programme: very short peptides (here, a four amino-acid sequence) are proposed to interact with gene promoter regions relevant to the tissue system the peptide is modelled on — in this case, vascular endothelium — modulating transcription of genes involved in endothelial cell maintenance and function. This is a substantially different and far less mechanistically established framework than classical receptor-based vascular pharmacology (e.g. nitric oxide pathway agents, ACE inhibitors).
Preclinical papers from the Khavinson group report that Vesugen has been observed to support markers of endothelial cell viability and proliferation in cultured vascular endothelial cells, particularly under conditions modelling age-related or oxidative endothelial stress. In aged rodent models, Vesugen administration is reported to be associated with improved microcirculatory parameters and markers of vascular wall integrity. These mechanisms are reported almost exclusively by the originating research group and have not been independently confirmed through Western peer-reviewed replication.
Research Areas & Reported Effects
Endothelial Cell Function
The core of Vesugen-specific research relates to vascular endothelial cell behaviour in vitro. Reported findings describe improved endothelial cell viability and proliferation markers under experimentally induced oxidative or age-related stress conditions, framed as supporting a role for Vesugen in endothelial maintenance research.
Microcirculation in Ageing Models
Several Khavinson-affiliated papers report improved microcirculatory flow parameters in aged rodent models following Vesugen administration, alongside markers suggestive of reduced capillary wall degeneration. These are presented as evidence for a general vascular-ageing research profile specific to this bioregulator.
Vascular Integrity and Age-Related Decline
Vesugen has been studied in models of accelerated vascular ageing for effects on markers of vessel wall structural integrity. Reported outcomes describe has been observed to support in structural and functional vascular markers relative to untreated aged controls, within the narrow scope of the Russian research literature available.
Research Data Summary
| Study / Model |
Reported Effect |
| Cultured Human/Animal Endothelial Cells (Khavinson et al.) |
Reported increase in endothelial cell viability and proliferation markers under induced oxidative stress conditions. |
| Aged Rat Microcirculation Model |
Reported improvement in capillary blood flow and microcirculatory parameters relative to untreated aged controls. |
| Rodent Vascular Ageing Model |
Reported markers suggestive of reduced age-related vascular wall degeneration. |
| Small-Scale Russian Human Study (older adults) |
Reported changes in circulatory and vascular parameters; not independently replicated outside Russian research settings. |
Stack Combinations Studied
- Vesugen + Ventfort → Research rationale: Ventfort is a related Khavinson-programme vascular-support formulation studied in Russian literature; the two have been examined together in vascular-ageing research contexts as complementary "vessel wall" bioregulator approaches.
- Vesugen + Epithalon → Research rationale: Studied together in some Russian longevity-focused protocols, pairing a vascular-tissue bioregulator with the broader pineal/longevity-associated bioregulator from the same research catalogue, for combined vascular and general-ageing marker research.
⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.
Research Protocol Reference
experimental research protocols only — not dosing recommendations.
| Protocol |
Dose (experimental model only) |
Duration (experimental model only) |
Frequency (experimental model only) |
Research Context |
| Rodent Research Protocol |
Model-dependent, mcg/kg range reported in Russian literature |
10-20 days |
Once daily |
Microcirculation and vascular ageing studies in aged rodents. |
| Russian Small-Scale Human Study Protocol |
Reported as intranasal administration in limited Russian trials |
10-day course |
As per study protocol |
Reported in small Russian clinical research on vascular and circulatory markers; not independently replicated. |
Observed Side Effects in Research
- No significant adverse events reported in the available Khavinson-affiliated literature
- Independent Western safety data is not available
- Long-term human safety data does not exist outside limited Russian research settings
Because independent Western toxicology and safety studies have not been conducted, the absence of reported side effects in the existing literature should not be read as an established safety profile.
Compound Data
- CAS Number
- Not consistently assigned in Western chemical registries
- Molecular Formula
- C15H24N4O9 (Lys-Glu-Asp-Gly tetrapeptide, approximate — not consistently cross-verified across Western chemical databases)
- Molecular Weight
- Approximately 400.4 g/mol
- Half-Life
- Not established in independently published pharmacokinetic literature
- Synonyms
- Lys-Glu-Asp-Gly, KEDG peptide, vascular/endothelial bioregulator peptide
- Research Classification
- Khavinson-class short peptide bioregulator, tissue-specific (vascular/endothelial) research peptide
Scientific References
The references below are drawn from Vladimir Khavinson's peptide bioregulator research programme. Readers should note this evidence base is almost entirely Russian preclinical and small-scale clinical research, published mainly in Russian-affiliated journals, and has not been replicated in Western randomised controlled trials. It should not be treated as equivalent in strength to Western RCT-based evidence.
- [Khavinson VK et al.] — Peptide regulation of vascular endothelial cell proliferation and viability in models of oxidative stress — Bulletin of Experimental Biology and Medicine — [In vitro / Russian research programme]
- [Khavinson VK, Anisimov VN et al.] — Short peptide bioregulators and models of vascular ageing — Advances in Gerontology — [Animal / mechanistic]
- [Khavinson VK, Malinin VV] — Gerontological Aspects of Genome Peptide Regulation — Karger monograph — [Theoretical / mechanistic framework]
- [Trofimova SV et al.] — Short peptides in the regulation of microcirculation and vascular tissue function in ageing models — Russian gerontology literature — [Animal / preclinical]
*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*